BIOSPACE: FDA Made the Right Call on Lilly’s Donanemab, Some Experts Say

FDA Made the Right Call on Lilly’s Donanemab, Some Experts Say January 24, 2023 Thursday, the FDA rejected Eli Lilly’s Alzheimer’s disease candidate, donanemab, an investigational antibody to ameliorate the symptoms of Alzheimer’s disease (AD). While the news may have disappointed the company, some AD experts asserted the FDA’s actions were appropriate. What’s more, Lilly’s approach with donanemab is…